{"name":"Cerevance","slug":"cerevance","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5DMHlSOFRoN2V4dXlBUFBFal9ITjh2SFVwMjdOM0xkdXU2bW5rVncwWjlZSjBqUmZBVUROYkF4WlZHd1kzYlNzOV9XRE51S0NPaGk3TzZJeVNCR2JSZ2R1Y3BlY0U2QzhSMmk1cDlSUEpTX1FhOFgxeG1B?oc=5","date":"2025-10-01","type":"pipeline","source":"Pharmaceutical Executive","summary":"NETSseq's Impact On Cerevance's Approach to Drug Discovery - Pharmaceutical Executive","headline":"NETSseq's Impact On Cerevance's Approach to Drug Discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOZFE0YWNCOUpsVjJwQWtIMURpeU45Vkxrd3dCbzVLSjdBbE9FbG1sZnJQcGFsZExLUy0wV3NScVZ5bWRqci0xWXFpaGJPdXdnT29vNzRCWE15ZU9ZM2lvcGNDTk83a1JEeXlfRV8zZWFzLVU1MlBFbVQ3YlprclVSYnhwYWt0OXBWX3ppcW1B?oc=5","date":"2025-09-30","type":"pipeline","source":"Pharmaceutical Executive","summary":"Key Scientific and Clinical Insights Leading to Cerevance's Pursuit of Solengepras - Pharmaceutical Executive","headline":"Key Scientific and Clinical Insights Leading to Cerevance's Pursuit of Solengepras","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNSE9UcUVIa3l6d1dFS1FFVjNnUFpFeklCcTdtbEVGc1hQdS02NjNBUDI1SmxEOXNlMkRGb0NpZ2VTT19UVzB5V2dma1FOUlM5eFRiM0RYY3ZzVDBvSE12NUlNb3RYbEQ3NFBKMW1pQlZLdHFtYTRsZ1VHazQ2V2pWa1BuLWVEUzVLVlpRWkdudWNzdEd2RUhDVk9n?oc=5","date":"2025-04-01","type":"trial","source":"Fierce Biotech","summary":"Cerevance fails phase 2 trial in early, untreated Parkinson's - Fierce Biotech","headline":"Cerevance fails phase 2 trial in early, untreated Parkinson's","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5TeTdzbGNNbjd6SkdBVXlCZ2wxOWFWM3BpRVVraGNjR21IYmoxSVB2Z3ZFY0JoMldPRkdWYXdyOW5rMHVCRmVWbzUtcERjdHY2cUJN?oc=5","date":"2025-04-01","type":"trial","source":"FirstWord Pharma","summary":"Cerevance's solengepras falls short in Phase II Parkinson's trial - FirstWord Pharma","headline":"Cerevance's solengepras falls short in Phase II Parkinson's trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE85WnF4dy0zcHEwY2MxbzlITWg3RjVYNEYwdjRtS1AwRVhuRklEQ2E2amNUdE1Lekd1SWVwWUZVRC1vSWNUV2JiQUJmamxQZWY0Z3lKTkRVU1dMSTdiZGRvZHlnQWFJa2IzdkpadVYtcw?oc=5","date":"2024-10-11","type":"pipeline","source":"Fierce Pharma","summary":"A revival in neuro therapeutics - Fierce Pharma","headline":"A revival in neuro therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQVE1KdllfdUZYRURwS2g4dUtKTkYtZUVfWFMwNDlnOVdDb0Vid3F6R1llZ3o0RzhabWk1UHhiT1FOVkpsZ3Mxd05CU3NtMkxJa19iR1dKMGw1S2Q1N1RqZGtXTk5pNTkxald4OVpBaGViR29GdHBNZHBWYm5yMVBibEg4STNuTl9Kb1o4cDFhdVE3c3ZGUmhj?oc=5","date":"2024-07-15","type":"pipeline","source":"Pharma Voice","summary":"Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders - Pharma Voice","headline":"Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE0xSDFwa0Fuc1pGQVVpbF9yMU55ZkdDYkUzVF9UU2JEZWhpSWJmbkZPY0NzeG90aFdFMEVCbkh4V2wyV2ViamhkSE1iQncwejFKdk5GN3ZNc0twTGtYSXNReEhId0U1QQ?oc=5","date":"2024-07-01","type":"pipeline","source":"The Pharma Letter","summary":"Cerevance - The Pharma Letter","headline":"Cerevance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOY3ZOdDdtN3JSQWZCd0o0UllHRks4SVFuS2VmeDVwblVjMHFRdGItc3hDVlotMXdfek9kLWpzMUZKaWdGUms5amJpaTZ2OVVXZ2FqdWxaajBqTVMyQjhkODFNZlBiN2gtR2JfVFNzb0QwZDJabzBZdjU4ZGdaLW1QckFxalZqZzJaSWdBN3lLOWg0UncxaGpzUA?oc=5","date":"2022-08-09","type":"pipeline","source":"BioSpace","summary":"Merck Returns to Alzheimer’s Disease with $1.1B Cerevance Pact - BioSpace","headline":"Merck Returns to Alzheimer’s Disease with $1.1B Cerevance Pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOX3Q5VGtIYmxSaUJOaUtkNW5xYUhoc3BOSlhZVElXR3JJem9MbkhiaG1tX1REYnFaSVlndTNJdk9ieWJYSDc0VVNEU05ndGp3WVpOYmFZVVpVUDdtSzFtWXZiUnBmZ19VQm04Z09xRmZ3MjJ5MkViWTdTaGFFRkRwMWVWUWpMS2hwQ2ludVRSYUpsVGNvSzFveFFRcE5Ndw?oc=5","date":"2022-08-09","type":"pipeline","source":"BioPharma Dive","summary":"A biotech startup gives Merck its next shot at treating Alzheimer’s - BioPharma Dive","headline":"A biotech startup gives Merck its next shot at treating Alzheimer’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPcko0M21rN1hNbWpTeFR1cXVkZ2t5SFNpVlFXMnN3dktQS1BfLXFDSHpMZUQtTUJfLUxidEJ2UlN2YTdpTmZlbjIxRUNzLTRWZUVWX3JuNXVNcWppZHBpT1NtTkNDWjA0Y1NmRmstanZCc3Z0UFBEWktlNVZweWtWc1BLV3JZQ09UZWlWZkVuWFFEQzhtcklrWUhlQ0x1S0kwUS00emQ5WVlTalNvemxRQVlxdldGWlRUVmJvYktjLUdJYmNuOWc?oc=5","date":"2022-08-09","type":"pipeline","source":"Fierce Biotech","summary":"Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE - Fierce Biotech","headline":"Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPT2lZMXBtYjV0eWVIN0NFV19qVVRzSkc5ZnpidWdfMVdBWGVqNTI4eFFQeUNDVTkyRUxZT0tqMXJDZmdCYjc5NEZXV1NBSnlDcnRKbHJycXphNmJSZjJjdXRIUkxSaENXaTRWbExBUU1NSThIYWZLYi0zdVVZNW42U0lZZWZCMW9nODF0OXNpS1JhZFBON0JKbGxkd3dHRjl6?oc=5","date":"2022-03-31","type":"trial","source":"pharmaphorum","summary":"After ph2 win, Cerevance preps pivotal trials of novel Parkinson's drug - pharmaphorum","headline":"After ph2 win, Cerevance preps pivotal trials of novel Parkinson's drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxObGJNOUozaVdQeFR5RW9RZ3Myb2V1WTVKelo5TmhKa2R3SDRyMkYtRERXQ0FyRi0zaFEycGp2ZmhvVXJ1ZUllbFBNSlJxMVliWENYbVNvN2ZMX293SUI0Q3gzaFNmZ3dMdGpkbkw3WlE3dmNBS1QxM24zaFUzcWpSWTJKUmR0dHRk?oc=5","date":"2020-04-21","type":"pipeline","source":"Pharmaceutical Technology","summary":"Breakthrough in neurodegeneration: GV, Bill Gates and Foresight invest $45m in Cerevance - Pharmaceutical Technology","headline":"Breakthrough in neurodegeneration: GV, Bill Gates and Foresight invest $45m in Cerevance","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}